

CAEP | ACMU ROADSHOWS

CME That Travels

AIME Airway Intervention & Management in Emergencies

September 5, 2014 - Truro NS
September 6, 2014 - Truro NS
September 25, 2014 - Whistler BC*
October 6, 2014 - Vernon BC
November 12, 2014 - Quebec City QC*
November 13, 2014 - Quebec City QC*
December 10, 2014 - Montreal QC
December 11, 2014 - Montreal QC

EDTU: Emergency Department Targeted Ultrasound

(Now 2 Day Course, Updated Curriculum)

November 1 & 2, 2014 - Toronto ON
November 1 & 2, 2014 - Vancouver BC
December 6 & 7, 2014 - Montreal QC

TX: Toxicology

August 24 & 25, 2014 - Muskoka ON
September 25, 2014 - Whistler BC

RB: Risky Business - Clinical Decision Making in Emergency Medicine

November 25, 2014 - Sudbury ON

ID: Infectious Disease Management in Emergency Medicine

October 16, 2014 - Regina SK

"NEW" Emergency Medicine Review

(Course Preview, it is Not Accredited)

August 22, 2014 - Muskoka ON

REGISTER NOW!

**In conjunction with a conference, registration through the respective conference, not via CAEP.ca. Contact CAEP for details.*



3 Ways to Register :

- Online at caep.ca
- Call 1-800-463-1158 ext. 14
- Download the registration form and fax completed form to 1-613-523-0190 (Attn: Carrol Ann)

Pr ONBREZ* BREEZHALER*

Helping to treat your symptomatic patients is all in a day's work...



Demonstrated fast, 5-minute onset (FEV₁ improvement shown 5 minutes after first dose 0.1 L; $p < 0.001$, serial FEV₁ measurement)^{††}



Maintained round-the-clock (24-hour) bronchodilation (LS mean FEV₁ (L) vs. placebo at week 12, $p < 0.001$; time points were 5 min, 30 min, 1 hr, 2 hrs, 4 hrs, 6 hrs, 12 hrs, 16 hrs, 22 hrs, and 24 hrs)^{1,2,††}

Improved transition dyspnea index (LS mean TDI focal score at week 12, 1.34 vs. 0.11 for placebo, $p < 0.001$)^{1,3§}

ONBREZ* BREEZHALER* The only ONCE-DAILY LABA in COPD[†]

Indication & clinical use:

ONBREZ* BREEZHALER* (indacaterol maleate) is a long-acting β_2 -agonist (LABA) indicated for long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

- Not indicated for the relief of acute deterioration of COPD, for asthma, or for use in patients under 18 years of age

Contraindications:

- Not indicated for treatment of asthma

Most serious warnings and precautions:

Asthma-related death: Increased risk of asthma-related death is considered a class effect with LABAs, including indacaterol maleate. ONBREZ* BREEZHALER* is not indicated for asthma.

Other relevant warnings and precautions:

- Not indicated for acute episodes of bronchospasm
- Increased risk of cardiovascular effects
- Caution in patients with cardiovascular disorders
- Caution in patients with convulsive disorders, thyrotoxicosis and patients who are unusually responsive to β_2 -adrenergic agonists
- Risk of hypokalemia and hyperglycemia
- Paradoxical bronchospasm
- Immediate hypersensitivity
- Should not be used in patients with acutely deteriorating COPD
- Should not be used concomitantly with other LABAs
- May inhibit labour

For more information:

Please consult the Product Monograph at www.novartis.ca/asknovartispharma/download.htm?res=onbrez%20breezhaler_scrip_e.pdf&resTitleId=482 for important information relating to adverse events, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling the Medical Information department at 1-800-363-8883.

FEV₁: forced expiratory volume in 1 second; LS: least square; TDI: transition dyspnea index.
† B2355: A 12-week, multicentre, randomized, double-blind, placebo-controlled, parallel group study assessing the safety and efficacy of ONBREZ* BREEZHALER* 75 mcg once daily vs. placebo in patients with COPD (n=318).
†† From a subset of 239 patients in B2355, FEV₁ data shown is ONBREZ* BREEZHALER* vs. placebo, respectively: 5 min: 1.56 vs. 1.39; 30 min: 1.57 vs. 1.38; 1 hr: 1.56 vs. 1.38; 2 hrs: 1.56 vs. 1.37; 4 hrs: 1.51 vs. 1.35; 6 hrs: 1.48 vs. 1.33; 12 hrs: 1.43 vs. 1.29; 16 hrs: 1.39 vs. 1.24; 22 hrs: 1.44 vs. 1.27; 24 hrs: 1.48 vs. 1.34.
§ B2354: A 12-week, multicentre, randomized, double-blind, placebo-controlled, parallel group study assessing the safety and efficacy of ONBREZ* BREEZHALER* 75 mcg once daily vs. placebo in patients with COPD (n=323).
¶ Comparative clinical significance has not been established.



Novartis Pharmaceuticals Canada Inc.
Dorval, Québec H9S 1A9
www.novartis.ca
☎ 514.631.6775 ☎ 514.631.1867

* ONBREZ and BREEZHALER are registered trademarks.
Product Monograph available on request.
Exp: 05/2014
© Novartis Pharmaceuticals Canada Inc. 2013



References: 1. ONBREZ* BREEZHALER* Product Monograph. Novartis Pharmaceuticals Canada Inc., October 24, 2012. 2. Data on file. Novartis Pharmaceuticals Canada Inc. Study B2355. 3. Data on file. Novartis Pharmaceuticals Canada Inc. Study B2354.



Once-daily
Pr onbrez*
breezhaler*
(indacaterol maleate inhalation powder)